经动脉药盒灌注治疗中晚期胰腺癌

目的评价经动脉药盒灌注盐酸吉西他滨、5-氟脲嘧啶（5-FU）和白细胞介素2（IL-2）对不同部位中晚期胰腺癌的治疗价值。方法回顾性分析63例不能手术切除的中晚期胰腺癌患者，经皮下动脉药盒系统灌注上述药治疗后不同部位胰腺癌的临床受益反应率（CBRR）和生存期。结果63例患者CBRR为44．4％，频数分布法计算中位生存期5．9个月，中位疾病进展期2．8个月。Kaplan-meier法计算6个月和9个月累积生存率分别为49．3％和26．8％。46例胰头癌患者和17例胰体尾癌患者6个月累积生存率分别为63．5％和40．6％，9个月分别为40．7％和12．3％。胰头癌患者和胰体尾癌患者CBRR分别为54．3％和17．6％（P〈0．01），中位生存期分别为9．1个月和4．3个月。中位疾病进展期分别为3．5个月和2．1个月。结论经皮下动脉药盒系统灌注上述药对中晚期胰腺癌患者有较高的CBRR，可延长其生存期；胰头癌的疗效优于胰体尾部。

The treatment of advanced pancrentic cancer by arterial infusion chemotherapy via port catheter system

Objective To evaluate the efficacy of arterial continuous infusing gemcitabine,(5-FU,)IL-2via port catheter system(PCS) in the tseatment of advanced pancreatic cancer.Methods(To retrospectively) analyze the clinical effectiveness of transarterial infusion chemotherapy of gemcitabine,5-FU and IL-2 via PCS in the treatment of 63 patients with advancedpancreatic cancer.Results(The) clinical benefitresponse rate(CBRR) in 63 cases was 44.6%.Medial survival time for all(patients) was 5.9 months,Median time to tumor progression was 2.8 months.The CBRR in 46(cases) with head-pancreatic cancer was 54.3%,which was obviously highdr than17.6% in 17 cases with body and end pancreatic cancer(P<0.01).Conclusion The continuous arterial infusion chemotherapy of gemcitabine,5FU and IL-2 via PCS can provide patients of advanced pancrentic cancer with higher CBRR,especially in those head pancreatic cancer.